Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: The past, the present and the future

Blood Transfusion

Volumn 12, Issue 3, 2014, Pages 314-319

  Jiménez Yuste, Victor ^a   Auerswald, Günter ^b   Benson, Gary ^c   Lambert, Thierry ^d   Morfini, Massimo ^e   Remor, Eduardo ^f   Šalek, Silva Zupanćić ^g  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Prof Hess Children's Hospital   (Germany)

^c Northern Ireland Haemophilia Comprehensive Care Centre   (United Kingdom)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^g KBC Zagreb   (Croatia)

Author keywords

Arthropathy; Haemophilia; Prophylaxis; Trough

Indexed keywords

BAY 79 4980; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOTTING PARAMETERS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; HALF LIFE TIME; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HUMAN; LOW DRUG DOSE; PROGNOSIS; PROPHYLAXIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; COMPLICATION; HEMORRHAGE; JOINT DISEASES;

HEMOPHILIA A; HEMORRHAGE; HUMANS; JOINT DISEASES;

EID: 84904628977     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0298-13     Document Type: Review

References (31)

1. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; Suppl 77: 3-132.
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
3. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
4. den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17: 41-4.
5. den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-53.
6. Skinner MW. WFH: closing the global gap-achieving optimal care. Haemophilia 2012; 18 (Suppl 4): 1-12.
7. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452-9.
8. Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008; 142: 250-6. (Pubitemid 351987306)
9. Dargaud Y, Wolberg AS, Luddington R, et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res 2012; 130: 929-34.
10. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56.
11. Dodd C, Watts RG. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center. Haemophilia 2012; 18: 561-7.
12. Fischer K, Steen CK, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-36.
13. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
14. Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012; 18: 369-74.
15. Lindvall K, Astermark J, Bjorkman S, et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855-9.
16. Fischer K, Astermark J, Van Der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-60. (Pubitemid 35446627)
17. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
18. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-902.
19. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.
20. Powell J, Martinowitz U, Windyga J, et al. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost 2012; 108: 913-22.
21. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11 (Suppl 1): 84-98.
22. Collins PW, Moss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305-12.
23. Ljung R, Auerswald G, Benson G, et al. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013; 19: 481-6.
24. Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
25. Powell JS, Nugent DJ, Harrison JA, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6: 277-83.
26. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
27. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
28. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23.
29. Santagostino E. PROLONG-9FP clinical development program - phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). Thromb Res 2013; 131 (Suppl 2): S7-10.
30. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
31. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res 2013; 131 (Suppl 2): S11-14.